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Abstract
Background: Multidrug resistance has emerged to both Plasmodium vivax and Plasmodium falciparum and yet the comparative
epidemiology of these infections is poorly defined.
Methods: All laboratory-confirmed episodes of malaria in Timika, Papua, Indonesia, presenting to community primary care
clinics and an inpatient facility were reviewed over a two-year period. In addition information was gathered from a house-to-
house survey to quantify the prevalence of malaria and treatment-seeking behaviour of people with fever.
Results: Between January 2004 and December 2005, 99,158 laboratory-confirmed episodes of malaria were reported, of which
58% (57,938) were attributable to P. falciparum and 37% (36,471) to P. vivax. Malaria was most likely to be attributable to pure
P. vivax in children under one year of age (55% 2,684/4,889). In the household survey, the prevalence of asexual parasitaemia was
7.5% (290/3,890) for P. falciparum and 6.4% (248/3,890) for P. vivax. The prevalence of P. falciparum infection peaked in young
adults aged 15–25 years (9.8% 69/707), compared to P. vivax infection which peaked in children aged 1 to 4 years (9.5% 61/642).
Overall 35% (1,813/5,255) of people questioned reported a febrile episode in the preceding month. Of the 60% of people who
were estimated to have had malaria, only 39% would have been detected by the surveillance network. The overall incidence of
malaria was therefore estimated as 876 per 1,000 per year (Range: 711–906).
Conclusion: In this region of multidrug-resistant P. vivax and P. falciparum, both species are associated with substantial
morbidity, but with significant differences in the age-related risk of infection.
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Background
The true burden of malaria outside of sub-Saharan Africa
has been underestimated [1], largely due to the lack of
accurate estimates from India and Indonesia, whose com-
bined population accounts for 20% of the world's popu-
lation. In Indonesia, almost half of the country's
population of 250 million live in malaria-endemic areas.
In Java and Bali, where approximately 70% of the coun-
try's population live, malaria is hypoendemic and vivax
malaria predominates. In the outer island groups, the
incidence of malaria is much higher with the prevalence
of Plasmodium falciparum and Plasmodium vivax infection
almost equal. According to the National Health House-
hold Survey in 2001, approximately 15 million people
with clinical malaria sought treatment [2], three million
of whom attend government health centres and hospitals.
However, the true incidence of malaria is unknown since
laboratory-confirmation is rare and only 20% of patients
with symptomatic malaria seek treatment at government
health facilities [3].
National statistics suggest an increase in malaria in Indo-
nesia over the last three years. Although this is a conse-
quence of several factors, the emergence and spread of
antimalarial drug resistance is likely to be a key determi-
nant. South-east Asia has been the focus for emerging drug
resistant strains of P. falciparum for more than 40 years,
but drug resistance in P. vivax has been slower to evolve.
The first chloroquine resistant isolates of P. vivax were
reported from Papua, Indonesia and Papua New Guinea
in 1989 [4,5]. These regions now have the highest rates of
drug-resistant P. vivax in the world [6]. A clinical drug
study conducted in southern Papua in 2004, highlighted
a risk of failure within 28 days of 65% after chloroquine
monotherapy for P. vivax and 48% after chloroquine plus
sulphadoxine-pyrimethamine for P. falciparum [7]. The
risk of of treatment failure elsewhere in Papua has reached
95% [8]. Recent studies from both the north and south of
Papua, have highlighted that multidrug-resistant P. vivax
in this region is associated with severe malaria and even
death [9,10]. As a consequence of the high levels of anti-
malarial drug resistance, first-line treatment of uncompli-
cated malaria, for any species of infection, was changed to
dihydroartemisinin-piperaquine in March 2006.
The aim of the present study was to document further the
epidemiology of malaria in this region prior to the intro-
duction of an artemisinin combination therapy, as part of
an ongoing analysis of the impact of policy change. To
achieve this a comprehensive epidemiological study was
conducted using surveillance data from primary and sec-
ondary health facilities and a cross-sectional malaria prev-
alence survey. At the same time a treatment-seeking
behaviour study was also conducted to estimate the bur-
den of malaria occurring outside this surveillance system.
Methods
Study site and population
The Mimika district lies on the southern coast of Papua in
Eastern Indonesia (Figure 1), covering an area of 21,522
Location of study area in Timika, southern Papua, IndonesiaFigure 1
Location of study area in Timika, southern Papua, Indonesia.
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square-kilometres with 12 sub-districts and 85 villages.
The area is largely forested with both coastal and moun-
tainous areas. Each year a total of approximately 5.5
metres of rainfall is recorded with peaks in July to Septem-
ber and December (unpublished data). At the last census
in 2004, the population in the lowlands was reported as
130,000. One hospital, the Rumah Sakit Mitra Masyarakat
(RSMM) in the town of Timika, services the whole district
and is the only hospital available for the lowland popula-
tion. Due to the presence of a local mine, there is eco-
nomic migration, with the local population increasing by
an estimated 16% per year. This has resulted in the diverse
ethnic origin of the local population, with highland
Papuans, lowland Papuans and non-Papuans all resident
in the region. Healthcare for the population is provided
by the public clinics of the local ministry of health, the
Public Health Malaria Control programme (PHMC) of
the mine, the RSMM hospital and the private sector.
Malaria transmission is perennial, but restricted to the
lowland area where it is associated with three mosquito
vectors: Anopheles koliensis, Anopheles farauti and Anopheles
punctulatus [11,12]. Entomological inoculation rates vary
between 1 and 4 infected bites per year (unpublished
data). Bed net coverage is estimated to be approximately
40%. In view of the high number of infections in non-
immune patients, local protocols recommend that all
patients with patent parasitaemia at any level are given
antimalarial therapy. At the time of the study local treat-
ment guidelines advocated chloroquine plus sulphadox-
ine-pyrimethamine for P. falciparum and chloroquine
monotherapy for non-falciparum malaria. An assessment
of local treatment regimens in 2004 highlighted that the
day-28 cure rate of chloroquine monotherapy was less
than 35% for patients with P. vivax and that of chloro-
quine plus sulphadoxine-pyrimethamine was only 52%
for patients with P. falciparum [7]. Local and national
guidelines also recommend that patients with P. vivax par-
asitaemia over 1 years old, receive 14 days unsupervised
treatment with primaquine, however adherence to and
effectiveness of this regimen in this setting is not known.
Study design
Data was collected from routine health facilities surveil-
lance data and from a cross-sectional survey.
Routine surveillance data
Data from health facilities were collated to determine the
number of patients treated for laboratory-confirmed
malaria between January 2004 and December 2005. The
established routine malariometric surveillance network
comprised 14 primary health clinics and the RSMM hos-
pital. Four primary health clinics were funded by the local
ministry of health and ten were funded by the public
health malaria control (PHMC) programme of the local
mine. The total number of malaria cases reported were
equally divided between the hospital, the PHMC clinics
and the local ministry of health clinics.
At all of these facilities malaria treatment guidelines
require that treatment should be preceded by microscopic
confirmation of thick or thin blood film. Parasite species
was assessed by surveillance facility microscopists from
Giemsa-stained thick blood films and peripheral parasi-
taemia determined from the number of parasites per 200
white blood cells and quantified as 1+, 2+, 3+ or 4+. A
thick smear was considered negative on initial review if no
parasites were seen in 100 high power fields. A thin smear
was also examined to confirm parasite species and used
for quantification if parasitaemia was greater than 200 per
200 WBC. All laboratories in the surveillance network
provide weekly aggregated data on the number of slides
read, and the species reported according to four age cate-
gories (less than 1 year, 1 to 4 years, 5 to 9 years and 10 or
more years). The surveillance microscopists participate in
ongoing quality assurance, training and monitoring. In
2004 the microscopy service at the hospital was assessed
for accuracy, and a random sample of 1200 positive slides
was selected for rereading by an independent micro-
scopist with more than 10 years' experience. In total,
slides were available in 97% (1,158/1,200) cases with
concordance between the readings of 89% (1,032/1,158).
Of the 126 discordant slides 18 (14%) were negative on
second rereading, 46 (37%) monoinfections were reread
as mixed species, 47 (37%) mixed infections were reread
as monoinfections. A further 6 slides with P. falciparum
infections were reread as P. vivax, and 9 slides with P. vivax
infections were reread as P. falciparum.
In the hospital, data were collected from individual
patient records. For those attending the hospital outpa-
tient clinic, information of the hospital number, date of
visit, age and sex of the patients and diagnosis, including
the species of infection if malaria, were registered on com-
puterized hospital records (Q-Pro_; Jakarta, Indonesia).
All patients admitted to hospital for more than 12 hours
were reviewed by a member of the onsite research team,
and details of their visit documented on a standard report
form which included, for this study, the hospital record
number, data of admission, age and sex of the patient [9].
Cross-sectional household survey
A cross-sectional survey, was conducted during July to
December 2005, to determine the demographic break-
down of the local population, the population prevalence
of malaria and anaemia, and document the treatment-
seeking behaviour and costs incurred by febrile illness.
The survey methodology and results will be described in
more detail separately. For the treatment seeking survey,
the sample size required to determine the true prevalence
Malaria Journal 2008, 7:148 http://www.malariajournal.com/content/7/1/148
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of households with someone with a recent history of fever
was based on an estimated prevalence of 40% and popu-
lation size of 140,000; a multiplication factor of 2 was
used to take into account the design effect due to cluster
sampling. A sample size of 800 households was required
to achieve an estimate of prevalence with greater than
95% confidence [13].
Households were chosen by three-stage cluster random
sampling, according to WHO guidelines [14]. Household
members were defined as anyone who lived under one
roof, ate from one kitchen and had resided in the study
area for at least six months. For each member, demo-
graphic information and fever history were recorded using
a standardized questionnaire. When the member was
present, weight and height were documented and a finger
prick of blood taken for blood film examination. Axillary
temperature was recorded and respondents defined as
symptomatic if they reported history of fever in the last 24
hours or had an axillary temperature of 37.5°C or above.
All household members who reported fever in the last
months were asked to complete a questionnaire on treat-
ment seeking behaviour.
Blood film examination
Blood film examination was carried out for all the facility
surveys. The peripheral parasitaemia was calculated
assuming a white cell count of 7,300 μl-1 1 [7]. All positive
blood films and 10% negative blood films were rechecked
in the National Institute of Health Research and Develop-
ment reference laboratory in Jakarta, and results that dif-
fered from those obtained in the unit laboratory were
reviewed by the two head laboratory technologists. Micro-
scopically confirmed malaria cases were treated according
to Indonesia Ministry of Health guidelines. Children and
adults found to be anaemic either on clinical examination
or after determination of haemoglobin levels were pro-
vided iron supplementation according to local guidelines.
Other common ailments detected clinically were also
treated.
Statistical analysis
Data on patients diagnosed with malaria were single
entered into Epi Info 6 (U.S. Centers for Disease Control
and Prevention, Atlanta, Georgia, USA) and data from the
household surveys double entered and validated using
EpiData 3.02 software (EpiData Asoociation, Odense,
Denmark). Analysis was performed using SPSS for Win-
dows (vs 15 SPSS Inc, Chicago, Illinois, USA) and STATA
statistical software (Version 8, Stata Corp. TX). The Mann-
Whitney U test or Kruskal-Wallis method were used for
nonparametric comparisons, and Student's t-test or one-
way analysis of variance for parametric comparisons. For
categorical variables, percentages and corresponding 95%
confidence intervals (95% CI) were calculated using Wil-
son's method. Proportions were examined using χ2 with
Yates' correction or by Fisher's exact test. Pyrogenic thresh-
olds were defined using the receiver operator curve, and
Youlden's Index calculated as sensitivity plus specificity
minus 1.
In order to estimate the annual population incidence of
malaria, data from the fever treatment seeking behaviour
study were used to estimate the proportion of patients
with malaria attending clinics participating in the surveil-
lance network. In case the treatment seeking behaviour of
patients with non-malarial fever differed significantly
from those with malaria, we used an algorithm to assign
each respondent a malaria diagnosis. This was done
according to whether malaria was confirmed by a blood
test, the treatment people received, and the status of the
blood film at the time of the household survey. A sensitiv-
ity analysis was performed by assuming best-case and
worse case scenarios where there was uncertainty in the
algorithm.
Ethical considerations
The study was approved by the Ethics committee of the
National Institute of Health Research and Development,
Indonesian Ministry of Health (Jakarta, Indonesia) and
the Ethics committee of Menzies School of Health
Research (Darwin, Australia). Written informed consent
was obtained from adult patients and parents of enrolled
children.
Results
Health facilities data
Between January 2004 and December 2005, 99,158 labo-
ratory-confirmed episodes of malaria were reported from
patients seeking treatment at health facilities in the sur-
veillance network. Of these, 68,802 (69%) were reported
from community outpatients, 24,334 (25%) hospital out-
patients and 6,022 (6.1%) from hospital admissions. Lab-
oratory confirmation of malaria was made in 27%
(68,802/253,987) of patients who had a malaria smear at
community clinics. At the hospital, 15% (24,334/
168,217) of the total outpatient workload and 34%
(6,022/17,823) of the total inpatient workload was attrib-
utable to patients with malaria (Figure 2). Although treat-
ment guidelines recommend that all patients have
microscopic confirmation of malaria prior to treatment, a
further 2,148 outpatients were reportedly diagnosed and
treated following clinical diagnosis, ie 8.1% (2,148/
26,482) of all outpatients treated for malaria.
Children under five years of age, accounted for 22%
(14,855/68,802) of community outpatients with malaria,
29% (7,029/24,334) of hospital outpatients and 34%
(2,050/6,022) of patients admitted to hospital (overall p
< 0.001).
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In total 58% (57,938) of cases had infection with P. falci-
parum and 37% (36,471) P. vivax (Table 1). The propor-
tion of malaria due to P. vivax was greatest in community
outpatients (42% 29,144/68,802), but fell to 25%
(6,181/24,334) in hospital outpatients and 19% (1,146/
6,022) in hospital inpatients (p < 0.001). In children
under one year of age malaria was most likely to be attrib-
utable to infection with pure P. vivax (overall 55% 2,684/
4,889) and this was apparent in all types of facility; overall
p < 0.001 (Figure 2). Malaria attributable to P. vivax fell to
43% (8,112/19,045) in children aged 1–4 years, to 33%
(4,029/12,096) in children 5 to 9 years old and 34%
(21,618/63,077) thereafter.
Household survey
Demographic data was gathered for 5,255 people from
825 households. Overall 46% (2,409) were female with
6% (92/1,441) of women of childbearing age pregnant.
Of the 5,255 respondents questioned 28% (1,494) were
highland Papuans, 26% (1,371) lowland Papuans, with
the remaining 45% (2,390) of non-Papuan origin. The
median age was 21 years [Interquartile Range: 8–32], with
17% (870) children aged less than 5 years (Figure 3). Of
the 3,284 adults (age > 15 years), 26% (866) reported
being housewives, 14% (456) were private employees, 9%
(299) were farmers and 20% (668) were unemployed. At
the time of interview, 3,896 household members were
present, with microscopy results available in 3,890, repre-
senting 74% of all household members. Absent members
Age-stratified proportions of total patient workload diagnosed with pure P. falciparum (dark bars), pure P. vivax (light bars) and mixed f lciparum and vivax infections at each type of healthcare facilityFigure 2
Age-stratified proportions of total patient workload diagnosed with pure P. falciparum (dark bars), pure P. vivax (light bars) and 
mixed falciparum and vivax infections (white bars) at each type of healthcare facility. Footnote: For each age group the lower 
number above the column is the total number of patients reviewed (= microscopy examinations in community clinics, or 
patients seen or admitted at the hospital) and the upper number represents the total number of patients with malaria.
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Table 1: Number of laboratory-confirmed malaria cases in 2 years of community and hospital surveillance (January 2004–December 
2005)
Total number of patients 
with confirmed malaria
P. falciparum P. vivax P. malariae Mixed Infections
Community outpatients 68,802 36,848 (53.6%) 29,144 (42.4%) 1,325 (1.9%) 1,485 (2.2%)
Hospital outpatients 24,334 16,895 (69.4%) 6,181 (25.4%) 382 (1.6%) 876 (3.6%)
Hospital inpatients 6,022 4,195 (69.7%) 1,146 (19.0%) 68 (1.1%) 613 (10.2%)
Total 99,158 57,938 (58.4%) 36,471 (36.8%) 1,775 (1.8%) 2,974 (3.0%)
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were most likely to be adults (76%, 1,032/1,359) of
whom 78% were male (805/1,032).
The overall prevalence of asexual parasitaemia was 16.3%
(634/3,890) with P. falciparum infection present in 290
(46%), P. vivax infection in 248 (39%), P. malariae in 24
(4%) and mixed infections in 72 (11%) (Figure 4a). The
prevalence of malaria varied with age. The median age of
respondents with P. falciparum parasitaemia was 19 years,
with prevalence peaking at 10% (69/707) in young adults
aged 15–24 years. In contrast, the median age of those
with P. vivax infection was significantly lower (13.5 years,
p = 0.01) with a peak of 9.5% (61/642) in children aged
one to four years (Figure 4a). The proportion of patients
with parasitaemia due to P. vivax infection was greatest in
infancy (67% 12/18) falling to 47% (61/130) in children
aged one to four years, with no change thereafter (overall
36% 175/486); p = 0.004 (figure 4b). The overall risk of
parasitaemia was 19% (402/2067) in Papuans, signifi-
cantly higher than in non-Papuans (12.7% 232/1,823); p
= 0.001. The relative proportion of parasitaemia attribut-
able to non-Papuans was 22% (66/230) in children under
15 years, but rose to 49% (166/338) in adults; p < 0.001
(Figure 4b).
Fever and parasite density
In total 68% (434/634) of respondents with asexual para-
sitaemia were asymptomatic (afebrile with no history of
fever in preceding 24 hours). Although this proportion
did not differ for P. falciparum, P. vivax, or mixed infec-
tions, asymptomatic carriage was significantly more likely
in people with pure P malariae infections (91.7% (22/24);
Odds Ratio = 5.3 [95%CI 1.2–33]), p = 0.023. Patients
with P. vivax parasitaemia were significantly less likely to
be afebrile if they were less than 1 year of age (33% 4/12)
compared to 75% (85/113) of older children and 70%
(86/123) of adults (p = 0.004 and 0.02 respectively),
although this age difference was not significant for the
other species (Figure 4a). The risk of fever did not vary
with sex or ethnicity.
The density of asexual parasitaemia of any species was sig-
nificantly higher if the patients were febrile (Table 2). A P.
falciparum parasitaemia above 1,734 μl-1 had a 57% (57/
100) sensitivity for predicting fever and a positive predic-
tive value of 61% (57/93). The corresponding threshold
for P. vivax was 310 μl-1, with parasitaemia above this level
having a sensitivity of 77% (56/73) and associated with
fever in 46% (56/122) of cases.
Estimated incidence
In 2005, a review of 13,766 laboratory records revealed
that 96.6% of patients with malaria had one blood film
for each episode of malaria, 3.25% had two blood films
and 0.13% had three films. The total number of cases
treated as community outpatients were therefore multi-
plied by 0.967 to account for multiple sampling. Hence
the total number of patients with confirmed malaria
reported by the surveillance network during the two-year
period was 95,886.
In the household survey, a history of fever within the last
month was reported in 35% (1813/5255) of household
members, of whom treatment seeking behaviour could be
Population by age group and gender in the community household surveyFig re 3
Population by age group and gender in the community household survey.
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a) Age-stratified parasitaemia prevalence rates in the household survey for P. falciparum, P. vivax and mixed infections for febrile (dark bars) and afebrile respond nts (light bars)Figure 4
a) Age-stratified parasitaemia prevalence rates in the household survey for P. falciparum, P. vivax and mixed infections for febrile 
(dark bars) and afebrile respondents (light bars). b) Proportions of all parasitaemic cases attributable to P. falciparum, P. vivax 
and mixed infections for Papuans (dark bars) and Non-Papuans (light bars).
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assessed in 1015 (56%). Of these respondents, 60% (607)
were estimated to have had malaria (based upon their
treatment and subsequent microscopy at the time of the
survey) of whom 39% (238/607) would have been diag-
nosed and thereby picked up by the surveillance network.
The sensitivity analysis defined the lower and upper esti-
mates as 37.7% (261/693) and 48% (206/426) respec-
tively. After correcting for multiple sampling at the
community clinics, the surveillance network identified a
total 47,943 reports of malaria per annum for a popula-
tion of 140,4000 people, representing 39% of the total
burden of malaria. The overall incidence of malaria, there-
fore, was estimated as 876 per 1,000 per year (Range:
711–906). The corresponding breakdown was 512
(Range: 416–529) for P. falciparum, 322 (Range: 262–
333) for P. vivax, 15.7 (Range: 12.7–16.2) for P. malariae,
and 26.3 (Range: 21.3–27.2) for mixed infections.
Discussion
The burden of P. vivax malaria from Asia has been under
appreciated, despite the region contributing almost 40%
of the world's malaria [1]. Plasmodium falciparum and P.
vivax are equally prevalent over much of the continent,
however P. vivax is usually assumed to be benign and its
associated morbidity often overlooked [6,8]. The situa-
tion has been further complicated by the emergence of
multidrug resistant Plasmodium. Over the last 50 years,
Asia has been the epicentre for the evolution and spread
of drug resistant isolates of P. falciparum. The latter have
subsequently spread to almost all regions of the malarious
world, undermining control programmes and signifi-
cantly exacerbating the burden of malaria [15]. Antimalar-
ial drug resistance in P. vivax has taken longer to emerge,
the first reports of chloroquine resistance coming from the
island of New Guinea in 1989 [4]. However, over the
ensuing two decades highly chloroquine-resistant P. vivax
has become increasingly prevalent in Papua province,
with reports of declining efficacy also documented across
the Indonesian archipelago as well as in Myanmar, India
and South America [6,16-18]. Despite this threat, few
studies have addressed the associated epidemiology of
malaria in areas where resistance has emerged to both P.
vivax and P. falciparum.
The study presented reviews the epidemiology of malaria
in patients attending community clinics and the only
referral hospital in southern Papua. In this region cure
rates following chloroquine plus sulphadoxine-pyrimeth-
amine have fallen below 50% for both P. falciparum and
P. vivax, with high grade resistance a significant problem
[7]. The results demonstrate that malaria accounts for a
considerable proportion of the total clinic workload
amounting to 15–27% of patients attending outpatient
clinics with fever and 34% of all hospital admissions. P.
vivax was responsible for 42% of malaria treated in the
outpatients and 19% of patients admitted to hospital with
malaria. In the household surveys, the overall prevalence
of malaria was 16%, lower than that reported in West
Sumba, Indonesia (31%) [19] and PNG (51%) [20],
although the proportion of carriage attributable to P. vivax
was higher: 39% in Timika compared to 32% in West
Sumba and 19% in PNG.
There were significant differences in the age-stratified rates
of infection (Figure 2). The workload due to malaria
peaked in the 5–14 age group, reaching 24% in hospital
outpatients and 42% in inpatients, however this was
mainly attributable to an increasing prevalence of clinical
infections with P. falciparum. In contrast, the burden and
proportion of P. vivax peaked in early childhood with
more than half of malaria in infants attributable to P.
vivax irrespective of healthcare facility. These findings con-
cur with studies from PNG, Vanuatu and Thailand [20-
22]. A notable feature of P. vivax infection is the presence
of the hypnozoite stage which in equatorial regions can
result in frequent relapse and recurrent symptomatic
Table 2: Prevalence of asexual parasitaemia in the community household survey.
Species Prevalence % (n/N) Proportion with Fever % (n) Geometric Mean Parasite 
count per μl-1 [95% CI]
Pf 7.5% (290/3890) With Fever 34% (100) 2,409 [1,535–3,781] P < 0.001
Without Fever 66% (190) 460 [362–583]
Pv 6.4% (248/3890) With Fever 29% (73) 1,074 [680–1,698] P < 0.001
Without Fever 71% (175) 292 [228–374]
Pm 0.6% (24/3890) With Fever 8% (2) 577 P = 0.295
Without Fever 92% (22) 279 [190–410]
Mixed 1.9% (72/3890) With Fever 35% (25) 1,812 [999–3,286] P = 0.09
Without Fever 65% (47) 971 [629–1,498]
Pf: Plasmodium falciparum; Pv: P. vivax; Pm: P. malariae; Mixed: two or more species
Malaria Journal 2008, 7:148 http://www.malariajournal.com/content/7/1/148
Page 9 of 10
(page number not for citation purposes)
infection. The predominance of P. vivax in infancy pre-
sumably reflects early exposure to infection, high rates of
subsequent recurrence and the rapid acquisition of immu-
nity. The additional impact of chloroquine resistance is
difficult to gauge, but likely to further exacerbate the
recurrence of malaria following partially effective treat-
ment. In contrast to the PNG study, in which children had
acquired almost complete immunity by the age of 9 years
old [20], both the present study and a study from Thai-
land observed a significant number of older children and
adults presenting with symptomatic P. vivax infections
[22]. In Papua, economic immigration has resulted in a
high proportion of the population being non-immune,
either Papuans from malaria-free highland areas or non-
Papuans from provinces with low endemicity. With little
or no prior exposure to malaria these migrants are vulner-
able to symptomatic infection into adult life. Indeed the
proportion of malaria carriage attributable to non-
Papuans rose with increasing age (Figure 4b), reflecting
not only their vulnerability to symptomatic infection, but
also their higher exposure to infection.
In the prevalence survey, approximately a third of patients
with peripheral parasitaemia reported an associated fever.
Although there was no difference in this proportion
between P. falciparum and P. vivax infections, the pyro-
genic thresholds differed considerably: 310 μl-1 for P. vivax
and 1,734 μl-1 for P. falciparum. The ability of P. vivax to
induce fever at lower levels of parasitemia than P. falci-
parum is well described [22,23] and is consistent with a
greater host inflammatory response during infections
with P. vivax, as evidenced by higher plasma concentra-
tion of fever-inducing cytokines, such as TNF, in vivax
malaria compared to P. falciparum infections with similar
parasitaemia [24,25]. Whereas the proportion of sympto-
matic P. falciparum carriage did not change with age, there
was a significant reduction in symptomatic carriage with
P. vivax, falling from 67% in infants to 28% in adults (Fig-
ure 4a). All patients with peripheral parasitaemia were
treated and, therefore, the proportion of asymptomatic
patients who would have become febrile if left untreated
can not be gauged.
Since the surveillance system did not include a prospec-
tive cohort an estimate of the incidence of clinical infec-
tion was derived from the clinic workload and a treatment
seeking behaviour survey. The latter will be reported more
fully in a separate paper, however the results highlight
that only 39% with symptomatic malaria would have
sought treatment at a facility in the surveillance network,
the majority either staying at home or seeking treatment
through the private sector or pharmacies. Extrapolating
the total number of reported malaria cases we estimated
an incidence of malaria of 512 and 322 per 1,000 popula-
tion per year for P. falciparum and P. vivax, respectively.
Conclusion
In conclusion, in Papua Indonesia both P. falciparum and
P. vivax are associated with significant morbidity. P. vivax
infection predominated in infancy with symptomatic
infections reducing with age, however even in adults this
species is responsible for a third of malaria treatments.
The presence of high grade chloroquine resistance in both
major Plasmodium species in this region, is likely to exac-
erbate the burden of disease due to the impact of partial
eradication and the inability to suppress or delay the
relapses from the liver stage of P. vivax.
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